COPENHAGEN, March 7 (Reuters) - Novo Nordisk's

global obesity drug rollout will be dominated by its

injectable medicines, while its oral version will be introduced

later in higher priced markets, the company's Chief Executive

Lars Fruergaard Jorgensen said on Thursday.

"I think we have the opportunity of demonstrating by far the

strongest efficacy compared to what we see being developed,"

Fruergaard told analysts at Novo's capital markets day.

"But it's not a technology that lends itself for dominating

global rollout, that will have to be injectable," he added.